Sangamo Therapeutics, Inc.(SGMO)

$0.07—

Chart

Sangamo Therapeutics, Inc.(SGMO)

OTCMARKET

$0.07—

Chart Studio

SGMO(SGMO)

SGMO

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-0.04

Aug 6, 2026

Revenue Estimate

$15M

FY2028E EPS$0.25

FY2029E EPS$0.49

Analyst Sentiment

Wall St. Consensus

Hold

13 analysts·Moderate coverage

Score

6 Buy (46%)6 Hold (46%)1 Sell (8%)

Rating Breakdown

Strong Buy

00%

Buy

646%

Hold

646%

Sell

18%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$2.00

+2602.7%

Consensus

$4.00

+5305.4%

Bull

$19.00

+25575.7%

12-Month Target Range13 analysts

$2.00$4.00$19.00

Current $0.07Consensus

Current Price

$0.07

Upside to Consensus

$3.93

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+92.49%

EPS—

FY2028

Rev+102.96%

EPS—

FY2029

Rev+50.11%

EPS+94.67%

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$68M	$130M	$264M	$396M	$540M
Low	$68M	$130M	$264M	$396M	$540M
High	$68M	$130M	$264M	$397M	$540M
EBITDA Avg	$-62M	$-118M	$-240M	$-361M	$-491M
Low	$-62M	$-118M	$-240M	$-361M	$-492M
High	$-61M	$-118M	$-240M	$-361M	$-491M
EBIT Avg	$-63M	$-122M	$-247M	$-371M	$-505M
Low	$-63M	$-122M	$-247M	$-371M	$-505M
High	$-63M	$-122M	$-247M	$-371M	$-505M
Net Income Avg	$-53M	$-15M	$70M	$136M	$214M
Low	$-53M	$-15M	$70M	$136M	$214M
High	$-53M	$-15M	$70M	$136M	$214M
EPS Avg	$-0.19	$-0.06	$0.25	$0.49	$0.76
Low	$-0.19	$-0.06	$0.25	$0.49	$0.76
High	$-0.19	$-0.05	$0.25	$0.49	$0.76
Analysts (Rev / EPS)	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$13M	$13M	$20M	$22M	$23M	$29M
Low	$13M	$13M	$20M	$22M	$23M	$29M
High	$13M	$13M	$20M	$22M	$23M	$29M
EBITDA Avg	$-12M	$-12M	$-18M	$-20M	$-21M	$-26M
Low	$-12M	$-12M	$-18M	$-20M	$-21M	$-26M
High	$-12M	$-12M	$-18M	$-20M	$-21M	$-26M
EBIT Avg	$-12M	$-13M	$-19M	$-20M	$-22M	$-27M
Low	$-12M	$-13M	$-19M	$-20M	$-22M	$-27M
High	$-12M	$-13M	$-19M	$-20M	$-22M	$-27M
Net Income Avg	$-27M	$-22M	$-14M	$-12M	$-12M	$-6M
Low	$-27M	$-22M	$-14M	$-12M	$-12M	$-6M
High	$-27M	$-22M	$-14M	$-12M	$-12M	$-6M
EPS Avg	$-0.07	$-0.06	$-0.04	$-0.03	$-0.03	$-0.01
Low	$-0.07	$-0.06	$-0.04	$-0.03	$-0.03	$-0.01
High	$-0.07	$-0.06	$-0.04	$-0.03	$-0.03	$-0.01
Analysts (Rev / EPS)	2 / 1	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Dec 31, 2024Jefferies

Sangamo price target lowered to $3 from $7 at Jefferies

Target:$3.00

+194.1%from $1.02

Dec 31, 2024Wells Fargo

Sangamo price target lowered to $2 from $3 at Wells Fargo

Target:$2.00

+96.1%from $1.02

Jun 13, 2022Wedbush

Sangamo assumed with a Neutral at Wedbush

Target:$5.00

+33.0%from $3.76

Apr 5, 2022Truist Financial

Sangamo BioSciences (SGMO) Stock: Why The Price Increased

Target:$19.00

+208.9%from $6.15

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance